Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119


TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.

Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L.

Anticancer Res. 2014 Feb;34(2):729-34.


Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.

Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.

Neurosurgery. 2009 Sep;65(3):610-24; discussion 624. doi: 10.1227/01.NEU.0000350227.61132.A7.


Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma.

Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, Jung HW, Lee DH, Kim SK.

Neuro Oncol. 2011 Jan;13(1):61-9. doi: 10.1093/neuonc/noq147. Epub 2010 Nov 9.


TRAIL-expressing gingival-derived mesenchymal stem cells inhibit tumorigenesis of tongue squamous cell carcinoma.

Xia L, Peng R, Leng W, Jia R, Zeng X, Yang X, Fan M.

J Dent Res. 2015 Jan;94(1):219-28. doi: 10.1177/0022034514557815. Epub 2014 Nov 12.


Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation.

Akimoto K, Kimura K, Nagano M, Takano S, To'a Salazar G, Yamashita T, Ohneda O.

Stem Cells Dev. 2013 May 1;22(9):1370-86. doi: 10.1089/scd.2012.0486. Epub 2013 Feb 4.


Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.

Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS.

Cancer Res. 2008 Dec 1;68(23):9614-23. doi: 10.1158/0008-5472.CAN-08-0451.


TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.

Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL.

Cancer Gene Ther. 2012 Sep;19(9):652-8. doi: 10.1038/cgt.2012.46. Epub 2012 Jul 6.


Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection.

Hu YL, Huang B, Zhang TY, Miao PH, Tang GP, Tabata Y, Gao JQ.

Mol Pharm. 2012 Sep 4;9(9):2698-709. doi: 10.1021/mp300254s. Epub 2012 Aug 15.


Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.

Yu R, Deedigan L, Albarenque SM, Mohr A, Zwacka RM.

Cell Death Dis. 2013 Feb 21;4:e503. doi: 10.1038/cddis.2013.19.


IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.

Yang X, Du J, Xu X, Xu C, Song W.

J Immunol Res. 2014;2014:318098. doi: 10.1155/2014/318098. Epub 2014 May 26.


Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors.

Martinez-Quintanilla J, Bhere D, Heidari P, He D, Mahmood U, Shah K.

Stem Cells. 2013 Aug;31(8):1706-14. doi: 10.1002/stem.1355.


The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.

Fei S, Qi X, Kedong S, Guangchun J, Jian L, Wei Q.

J Cancer Res Clin Oncol. 2012 Feb;138(2):347-57. doi: 10.1007/s00432-011-1104-z. Epub 2011 Dec 4.


Human mesenchymal stem cells with adenovirus-mediated TRAIL gene transduction have antitumor effects on esophageal cancer cell line Eca-109.

Li L, Li F, Tian H, Yue W, Li S, Chen G.

Acta Biochim Biophys Sin (Shanghai). 2014 Jun;46(6):471-6. doi: 10.1093/abbs/gmu024. Epub 2014 Apr 15.


MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.

Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K.

Cancer Res. 2007 Oct 1;67(19):8994-9000.


Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.

Loebinger MR, Eddaoudi A, Davies D, Janes SM.

Cancer Res. 2009 May 15;69(10):4134-42. doi: 10.1158/0008-5472.CAN-08-4698. Epub 2009 May 12.


Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.

Yulyana Y, Endaya BB, Ng WH, Guo CM, Hui KM, Lam PY, Ho IA.

Stem Cells Dev. 2013 Jul 1;22(13):1870-82. doi: 10.1089/scd.2012.0529. Epub 2013 Mar 26.


In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.

Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F, Silvestris F.

Br J Haematol. 2012 Jun;157(5):586-98. doi: 10.1111/j.1365-2141.2012.09082.x. Epub 2012 Mar 16.


Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK.

Kim SW, Kim SJ, Park SH, Yang HG, Kang MC, Choi YW, Kim SM, Jeun SS, Sung YC.

Clin Cancer Res. 2013 Jan 15;19(2):415-27. doi: 10.1158/1078-0432.CCR-12-1568. Epub 2012 Nov 30.


The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.

Jiao H, Yang B, Guan F, Li J, Shan H, Song L, Hu X, Liang S, Du Y, Jiang C.

Neurol Res. 2011 May;33(4):405-14. doi: 10.1179/016164110X12816242542490.


Supplemental Content

Support Center